Efficacy and Safety of Glimepiride With or Without Linagliptin Treatment in Patients With HNF1A Diabetes (Maturity-Onset Diabetes of the Young Type 3): A Randomized, Double-Blinded, Placebo-Controlled, Crossover Trial (GLIMLINA).
Alexander S ChristensenSofie HædersdalJulie StøyHeidi StorgaardUlla KampmannJulie L FormanMarta SeghieriJens Juul HolstTorben HansenFilip K Krag KnopTina VilsbøllPublished in: Diabetes care (2020)
Linagliptin as add-on treatment to glimepiride improved glycemic variability and control without increasing risk of hypoglycemia in patients with HNF1A diabetes.